Patent No. EP3700529 (titled "New Combination Of Active Agents For The Treatment Of Progressive Fibrosing Interstitial Lung Diseases (Pf-Ild)") was filed by Boehringer Ingelheim on Oct 12, 2018. The application was issued on Jul 9, 2025.

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents